Diplomat Pharmacy (DPLO) Tops Q1 EPS by 4c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Diplomat Announces 1st Quarter Financial Results
May 8, 2017 4:20 PM EDTFLINT, Mich., May 8, 2017 /PRNewswire/ --Â Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended March 31, 2017. Â All comparisons, unless otherwise noted, are to the quarter ended March 31, 2016.
First Quarter 2017 Highlights include:
Revenue of $1,079 million, compared to $996 million, an increase of 8% Total prescriptions dispensed of 220,000, compared to 232,000 Gross margin of 7.9% versus 8.0% Gross profit per prescription dispensed of $383, compared to $332 Net income attributable to Diplomat of $4.4... More